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The estrogen receptor-alpha (ER) is involved with the pathogenesis and therapy of ER-
positive (ER+) breast cancers.  ER signaling is complex, though many mediators of ER 
signaling have been identified.  Specifically, phosphorylation of ER at serine 118 affects 
responses to estrogen and therapeutic ligands, and has been correlated with clinical 
outcomes in ER+ breast cancer patients.  We have identified a novel, naturally-occurring 
germline variant by which ER serine 118 is replaced with a proline residue (S118P).  We 
have developed and characterized human isogenic breast epithelial cell line models 
carrying the ER S118P variant to determine the functional effects of this variant. 
Surprisingly, in heterozygous knock-in models, S118P cells demonstrate no significant 
change in proliferation, migration, signaling, or response to the endocrine therapies 
tamoxifen and fulvestrant.  We also examined the frequency of this variant in families at 
high risk for breast cancer and concluded that it is not enriched in this population.  This 
work suggests that ER S118P does not affect the risk of breast cancer incidence, and 
importantly, breast cancer patients harboring this variant are not likely to have altered 
responses to current endocrine therapies. 
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Breast cancer background 
 
 Breast cancer is currently the most-diagnosed cancer in women in the US, with 
over 250,000 new cases expected annually.  Over 40,000 deaths per year in the US are 
attributed to breast cancer, and there are millions of survivors being treated and 
monitored throughout the country at any one time.   
 Breast cancer is a disease of the epithelial cells which line the ducts and lobules 
of breast tissue.  Genetic alterations in these cells can result in cell cycle dysregulation 
and uncontrolled cell growth. Under the proper conditions, these cells may establish a 
tumor and eventually breach the epithelial basal membrane, becoming a bona fide 
invasive carcinoma.   
 Breast cancers are often classified according to several pathological factors upon 
diagnosis: whether the tumor cells originated in the ducts or lobules of the breast; 
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whether they derive from basal- or luminal-type epithelial cells; and the expression of 
three key receptors on the cell surface—the estrogen receptor-α (ER), the progesterone 
receptor (PR), and the human epidermal growth factor receptor 2 (HER2).   
ER is expressed in approximately 70% of breast cancers, usually in tandem with 
other markers that are often found in luminal breast epithelial cells; ER-expressing (ER+) 
breast cancers have thus been deemed luminal-type. This group has been further 
divided into luminal A and luminal B subtypes, distinguished by significant expression of 
proteins such as HER2 or Ki67 in luminal B tumors. Luminal A type breast cancer is 
generally associated with a better prognosis than the other breast cancer subtypes due 
to a combination of factors: it tends to be more differentiated and less aggressive than 
other subtypes, the rate of recurrence is lower and slower, and there are ever-
increasing numbers of targeted therapies against ER and ER-related signaling being 
developed and approved for treatment of this disease subtype. Generally speaking, 
most but not all luminal A type breast cancers are ER+ and HER2- for receptor 
expression. 
However, the positive outlook associated with ER+ breast cancer turns out to be 
relatively short term.  ER+ breast cancer patients who have been treated with standard 
of care targeted therapies continue to have significant rates of recurrence over twenty 
years post-diagnosis (1).  The fact that ER+ patients continue to experience recurrence 
of disease over such a long period provides a rationale for continuing to develop and 




The estrogen receptor-alpha and estrogen signaling 
The ER protein, encoded by the gene ESR1, is a nuclear steroid hormone 
receptor which acts as a transcription factor to regulate proliferation and differentiation 
of cells in which it is expressed.  Estrogen signaling via ER plays a major role in elements 
of the female reproductive cycle such as ovulation and mammary gland development, 
and ER is highly expressed in corresponding tissues such as the ovaries and breasts and 
has been linked to carcinogenesis in those tissues.   
The approximately 70% of breast cancers which express ER are dependent on 
estrogen signaling for tumor growth and maintenance.  In “classical” ER signaling, 
binding of the ligand estrogen to ER induces dimerization to form an activated 
transcription factor, which can then regulate transcription of many downstream genes 
(Figure 1).  In addition to a ligand-binding domain (LBD), ER contains a DNA-binding 
domain which recognizes estrogen response elements (EREs) in the genome and a 
transactivation domain which induces changes in transcriptional activity at EREs upon 
ligand-dependent receptor activation and DNA binding.  A number of co-activators and 
co-repressors have been shown to form complexes with ER in order to modulate its 
activity—the balance of co-activator/co-repressor expression in different tissues and 
under different cellular conditions is thought to be a major factor in ER functionality and 
even tissue-specific responses to endocrine therapies targeting ER signaling in the 
cancer setting.(2, 3) 
In “non-classical” ER signaling, ER can alternatively interact with non-ERE 
genomic loci and/or become activated under ligand-independent conditions, and 
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participates in crosstalk with several other major signaling pathways in the cell, 
including the MAP Kinase and PI3 Kinase pathways (4, 5). Transcription factors such as 
AP-1, Sp1, and NFKB can interact with ER, conferring the ability to recognize non-
traditional response elements for transcriptional activation (6).  Interactions with 
coactivators and corepressors can also affect ER’s cellular location, responsiveness to 
ligand, and transcriptional activity (7, 8).  Additionally, post-translational modifications 
to ER that occur downstream of several receptor tyrosine kinases and G-protein coupled 
receptors can induce ligand-independent ER signaling. This includes modulating three 
well-characterized phosphorylation sites of ER which can be acted upon by important 
additional kinases such as MAP kinase, Akt, protein kinase A, and HER2 respectively (9, 
10).  The integration of these well-described pathways with ER activity has profound 
implications for normal ER function, as well as its role in cancer and resistance to 
endocrine therapies.  For example, phosphorylation of ER by HER2 and other kinases 
may circumvent estrogen-dependence of ER activation, contributing to resistance to 
anti-estrogen endocrine therapies (11).  ER is also capable of non-genomic signaling 
activities, and has been described to have non-nuclear activity via interactions with a 
number of important cellular signaling factors, most notably proteins within the MAP 
kinase signaling pathway (12).   
 
Endocrine therapies 
The difficult-to-tolerate side effects of systemic chemotherapy have led to 
efforts to identify and develop targeted cancer therapies wherever possible.  The crucial 
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role of ER in luminal breast cancer has led to widespread use of three broad classes of 
endocrine therapies against ER signaling in the breast (Figure 2).   
A class of drugs deemed selective estrogen receptor modulators (SERMs) confers 
a change in ER activity based on conformational change and/or co-repressor binding.  All 
SERMs are partial ER agonists, exhibiting anti-proliferative activity in breast tissue but 
estrogenic activity in other peripheral tissues such as endometrium and bone, 
depending on the particular SERM (13).  In randomized clinical trials, the first-generation 
SERM tamoxifen has performed well and subsequently been approved for prevention of 
breast cancer in high-risk patients, as an adjuvant treatment for early disease in pre- and 
postmenopausal women, and as first-line therapy in metastatic breast cancer.  
However, tamoxifen use is associated with increased risk of endometrial cancer and 
thromboembolic events.  Raloxifene, a second-generation SERM, is also used for 
prevention of breast cancer and has shown a reduction of side effects, notably 
endometrial cancer, when compared with tamoxifen in breast cancer clinical trials 
(although raloxifene’s primary use is in the treatment of osteoporosis) (13).  
Importantly, raloxifene is not used for the treatment of breast cancer.  Several third-
generation SERMs are currently under investigation in clinical trials, including 
toremifene, which has been used successfully in the early adjuvant and metastatic 
settings but has a safety profile similar to that of tamoxifen and bazedoxifene.   
Selective estrogen receptor down-regulators (SERDs) such as fulvestrant reduce 
ER activity and induce its proteasomal degradation.  Unlike SERMs, fulvestrant and other 
SERDs exhibit full antagonistic activity of ER in all tissues.  Fulvestrant is currently a 
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second-line endocrine therapy given to postmenopausal ER+ breast cancer patients with 
advanced disease, and promising results from recent clinical trials indicate that it may 
be used in other settings as well, such as first-line therapy and in premenopausal 
patients (14, 15).  In addition to fulvestrant, two candidate SERDs with improved 
bioavailability are being evaluated in Phase I clinical trials (16, 17).  These latter two 
SERDs have the significant advantage of oral formulations, compared to fulvestrant 
which requires monthly gluteal intramuscular injections. 
The final class of ER-targeted endocrine therapies, the aromatase inhibitors (AIs), 
greatly reduce production of estrogen in the body, thus removing the main source of ER 
activation.  This class includes the steroidal AI exemestane, as well as the non-steroidal 
AIs letrozole and anastrazole.  AIs can only be used in post-menopausal women or pre-
menopausal women who no longer have ovarian production of estrogen, either through 
surgical removal of the ovaries or from lutenizing releasing hormone agonists, such as 
goserelin.  This is because ovarian production of estrogen does not rely upon 
aromatase, an enzyme that is a cytochrome P450 family member.  In the post-
menopausal state, aromatase is the major if not exclusive source of estrogen 
production, and AIs for these patients have been proven to be superior to tamoxifen in 
the majority of trials.  Thus, these drugs constitute the standard first-line adjuvant and 






Endocrine therapy resistance  
Although all three drug classes are used effectively in patients with ER+/HER2- 
breast cancer, resistance to these therapies has become a major hurdle (11).  Almost 
half of ER+/HER2- patients do not respond to endocrine therapies, termed primary or de 
novo resistance.  In addition, the majority of metastatic patients who initially respond to 
endocrine therapies will eventually progress or relapse, termed secondary or acquired 
resistance.   The mechanisms for resistance have not been fully elucidated, but depend 
upon estrogen-independent survival and proliferation of the tumor cells.  This can result 
from ER mutations which lead to constitutive ligand-independent activation of the 




Due to challenges with resistance to endocrine therapies, additional options for 
the treatment of ER+/HER2- breast cancer have emerged and others are under 
investigation.  As in other cancers, it is thought that combination therapies, by halting 
multiple signaling pathways at once, will prevent ER+/HER2- tumors from evolving 
compensatory mechanisms to bypass ER signaling.  Therefore, a number of non-
endocrine targeted agents have been tested in combination with endocrine therapies 
and more studies are underway.  Several promising agents have been identified and are 
now approved therapies for ER+/HER2- disease. 
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Complex crosstalk between PI3 kinase/mTOR and ER signaling pathways suggests 
that targeting of both pathways could be detrimental to ER+ tumor growth (18).  For this 
reason, the BOLERO trials tested the hypothesis that the mTOR inhibitor everolimus in 
combination with current endocrine therapies could improve outcomes for metastatic 
ER+ patients with endocrine therapy resistant disease.  Improved outcomes 
demonstrated by the BOLERO-2 trial have resulted in approval of the combination of 
everolimus and exemestane for clinical use in advanced ER+ breast cancers (19).  
Further BOLERO studies will test everolimus in combination with other endocrine agents 
such as letrozole and in additional breast cancer settings such as premenopausal and/or 
endocrine-naïve patients (20).  
Another hypothesis posits that cell cycle arrest could enhance endocrine therapy 
(21).  The CDK 4/6 inhibitors palbociclib and ribociclib are therefore interesting 
candidates for combination therapy, and numerous trials have been initiated with these 
agents.  Early results of the PALOMA trials have demonstrated improved outcomes with 
palbociclib in combination with certain endocrine therapies including letrozole and 
fulvestrant and further studies are underway (20, 22).  This has led to the FDA approval 
of letrozole and palbociclib for first line therapy in metastatic ER+/HER2- breast cancer 
patients. 
Finally, HDAC inhibitors such as entinostat may deregulate ESR1 transcription 
sufficiently to overcome endocrine resistance.  The ENCORE 301 study demonstrated 
improved outcomes with entinostat and exemestane combination therapy and 
confirmatory trials are underway (19).   
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On the other hand, studies of several additional classes and combinations of 
targeted agents have met with limited success in ER+ breast cancers.  Anti-angiogenic 
agents, multi-target kinase inhibitors, EGFR inhibitors, and poly-endocrine therapy did 
not significantly improve outcomes in their respective trials but may benefit from the 
identification of biomarkers that can select for patient populations most likely to benefit 
from these therapies either singly or in combination.  
 
Amplification of ESR1 
 Although ER is highly expressed in a large proportion of breast cancers, it 
appears that this is largely not a product of ESR1 amplification.  This issue was 
controversial after a 2007 fluorescent in situ hybridization study indicated that 
significant ESR1 amplification was present in over 20% of breast cancers (23).  Later 
studies failed to replicate this rate of amplification and it was eventually suggested that 
accumulation of ESR1 transcripts in the nucleus may have been responsible for the 
perceived amplification and its association with strongly ER+ breast cancer (24).  
However, another recent study found that amplification of ESR1 occurred in MCF7 cells 
(a widely used breast cancer cell line) after long-term estrogen deprivation, which may 
model the paradoxical clinical phenomenon in which long-term endocrine therapy in a 
small subset of patients leads to estradiol hypersensitivity (25).  In this group, estradiol 
may be useful as a breast cancer therapy which causes apoptosis in hypersensitive cells, 





 With the understanding that all cancers are genetic diseases, it is surprising that 
genetic alterations in ESR1 are rarely found in ER-driven primary breast tumors. Early in 
vitro mutagenesis studies of ESR1 identified dominant-negative and ligand-independent 
forms of the ER protein (26) and in vivo and clinical studies identified acquired 
mutations which mediate the effects of tamoxifen (27, 28), but large clinical surveys 
have shown that ER variants are rare in primary breast cancer (29).  This knowledge 
from early tumor-sequencing studies led to the notion that ESR1 gene alterations are 
not involved with breast carcinogenesis despite the importance of ER signaling for 
therapeutic intervention in the majority of breast cancer patients.   
 However, it has been suggested that ER variants play a role in advanced breast 
cancer (30) and indeed, contemporary studies have identified rearrangements and 
recurrent somatic mutations of ESR1 in metastatic hormone-resistant disease (25, 31-
34).  Each of these studies has detected a significant rate of ESR1 mutation or variation 
(Table 1).  In various forms, the authors of these studies suggest that the low-estrogen 
conditions achieved by the endocrine therapies favor somatic variation of ESR1 in order 
for tumor cells to adapt and thrive, and these mutations are now known to be 
mediators of resistance to endocrine therapies.  Thus, although the known ESR1 
mutations are not likely to be involved with the development of breast cancers, the 
recognition of ESR1 mutations in metastatic disease may lead to newer therapies that 
can overcome resistance for therapeutic benefit.  
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Notably, there appears to be a mutational hot spot region in the ER LBD at 
residues 536-538, which includes a tyrosine phosphorylation site at residue 537 (Figure 
3).  Mutagenesis studies have identified the critical role of these amino acids in 
regulation of ER activity (35, 36).  A number of different substitutions within this hot 
spot have been shown to confer constitutive ligand-independent activation of ER, 
suggesting that these naturally-occurring mutations play a role in acquired resistance to 
endocrine therapies (25, 31-34).  These residues lie within helix 12 of the LBD, which is 
responsible for closing the LBD pocket upon ligand binding and creating a surface with 
which co-regulators can interact.  As shown in structural modeling of one particular LBD 
mutation, D538G, changes to helix 12 can result in a conformational change that, even 
in the absence of ligand, mimics the ligand-bound form of ER (34).  This not only 
precludes binding of ligands such as estradiol, tamoxifen, and fulvestrant but also allows 
ligand-independent co-activator recruitment.  Finally, this ligand-independent ER has 
constitutive transcriptional activity at EREs and may contribute to enhanced cell 
proliferation and migration (34).   
A study of patient-derived breast cancer xenografts, which also detected LBD hot 
spot mutations, noted one chromosomal translocation between the coding regions of 
ESR1 and YAP1 leading to an in-frame, expressed fusion protein (25).  Much like two 
previously identified naturally-occurring ER fusion proteins, the N-terminus of ER 
containing the DNA-binding domain and AF1 transactivation domain was preserved but 
the C-terminus was replaced by that of YAP1—thus losing the LBD and AF2 
transactivation domain of ER.  Although the resulting physical properties of this protein 
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are quite different from the LBD mutations discussed above, this fusion protein similarly 
gained ligand-independence while preserving DNA-binding and transactivation function.  
However, while LBD point mutations will alter ligand affinities and contribute to 
resistance to particular endocrine therapies, complete loss of the LBD as in these fusion 
proteins leads to an “intrinsic and universal endocrine-therapy resistance” which will 
need to be addressed with different clinical strategies (25).  While clearly occurring at a 
low frequency, the recurrence of this type of fusion protein across three studies 
indicates that the effect is robust and almost certainly drives endocrine therapy 
resistance in this small subset of patients.   
While the effects of the LBD mutations and such fusion proteins have been 
explored, there are still ER variants awaiting study. Less frequent missense mutations 
have been identified in clinical trials by several groups (37-39) and it is unknown how 
these variants affect ER signaling activities within the cell.  One interesting variant, 
known as ER S118P, will be the focus of Chapter 2.  
 It is likely that ER variants can be categorized according to the type of endocrine 
therapy that they resist:  SERM and SERD resistance depends upon changes to the 
protein’s interaction with the drug, while AI resistance depends upon estrogen-
independent activity of the receptor or of the cell itself.  Since ER varies widely in its 
affinity for various ligands, it may be that each individual LBD mutation will confer a 
different effect on each individual receptor-ligand interaction, which will have profound 
effects on endocrine therapy decisions for patients with these mutations.    
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 Finally, it cannot be ignored that these mutations were identified only after the 
recent practice of obtaining metastatic biopsies for sequencing.  Although some studies 
have suggested that these LDB mutations are present in primary tumors (33), most 
studies have not validated these results.  More importantly, we now understand based 
on these studies and others that a single biopsy from the primary tumor is usually not 
representative of a patient’s heterogeneous and ever-evolving tumor cell population.  
For example, some of the aforementioned studies of ESR1 mutations identified 
mutations in one site of disease but not in other metastatic sites within the same 
patient (33, 34).  In this respect, we have demonstrated that a “liquid biopsy” technique, 
which is representative of all disease sites in the body including micrometastatic 
disease, can detect low-frequency mutations including those in ESR1 (40).  We speculate 
that in the future this will provide additional information to make the best treatment 
decisions.  Thus, the lesson learned from cancer genome sequencing studies over the 
past decade is that profiling a patient’s primary tumor may be inadequate to truly 
understand the molecular evolution of metastatic disease.  In this regard, liquid biopsies 
may allow a more comprehensive profiling of a patient’s total disease burden, and for 
ER positive disease, further characterization of ESR1 variants.  This, along with ongoing 








The characterization of clinically relevant ESR1 variants and their sensitivity to 
various endocrine therapies will be crucial for optimal treatment for this subset of ER+ 
breast cancers.  The advent of molecular profiling and precision medicine brings the 
opportunity to account for these ESR1 variants and treat patients accordingly.  While 
new therapies may be needed for certain variants, higher doses of already approved 
therapies may afford near term benefit, a testable hypothesis for clinical trials.(34)  In 
addition, the continued development of newer SERMs and SERDs, along with novel 
therapeutic combinations, may allow for improved outcomes for patients with 
















Figure 1: Estrogen and ER signaling. Estrogen (E2)-induced activation of the estrogen 
receptor leads to proliferation, differentiation, and cell survival. Classical ER signaling 
consists of a genomic or transcriptional response, and non-classical ER signaling involves 




Figure 2: Targeted therapies against ER. Targeted therapies for ER+ breast cancer 
consist of endocrine therapies, including AIs, SERMs, and SERDs, as well as targeted 















Figure 3: ER protein ligand-binding domain mutations. The gene ESR1 encodes the 
nuclear receptor protein estrogen receptor-alpha, containing domains responsible for 
DNA binding, transactivation functions 1 and 2, and ligand binding.  The most common 
ESR1 mutations result in variation of the ligand binding domain at residues 536, 537, 
and 538.  These residues are part of Helix 12 of the ligand binding domain, which is 
known to regulate ligand binding and recruitment of co-repressors and co-activators, 













Study ER variant types detected n Variant rate 
Li et al 2013 Amplification, fusion, mutation 7 57% 
Merenbakh-Lamin et al 2013 Mutation 13 38% 
Robinson et al 2013 Mutation 11 55% 
Toy et al 2013 Mutation 80 18% 
Jeselsohn et al 2014 Mutation 76 12% 
 
Table 1: ER variant rates. In 2013 and 2014, five studies detected a significant rate of ER 























 Due to the importance of ER-targeted therapies for patient care, it is crucial to 
identify patients whose disease may be resistant to this class of drugs.  While various 
studies have described resistance mechanisms (41) including constitutive ER activation 
in metastatic disease via mutations in the ER ligand binding domain (LBD) (25, 31-34), 
most patients with hormone therapy-resistant ER+ disease are identified by disease 
progression and the molecular mediators of their resistance are unknown.   
 Review of next generation sequencing data from metastatic patient samples 
from the Johns Hopkins Molecular Tumor Board and other studies revealed several 
patients with an unusual ESR1 variant (37-39).  This single-nucleotide substitution 
results in a non-synonymous substitution of serine to proline at residue 118 of ER (ER 
S118P), in the region of the DNA-binding and transactivation function 1 domain of the 
protein.  Serine 118 is an important phosphorylation site dictating ER activity levels as 
well as associations with coregulators and estrogen response elements (8).  S118 
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phosphorylation has been well-characterized and is mediated by several kinases such as 
MAPK, mTOR, and CDK2 (42, 43).  Therefore, in addition to the potential change in 
protein structure resulting from this substitution, it also constitutes loss of a crucial 
regulator of ER signaling.  Phosphorylation at serine 118 has also been shown to 
correlate with tamoxifen resistance (44).  Multiple studies have shown profound 
differences in ER function upon S118 mutation to alanine or glutamic acid, precluding or 
mimicking phosphorylation, respectively (8, 41, 45).  Due to the importance of the S118 
residue in ER function, we hypothesized that S118P may be involved in ER+ breast 
cancer pathogenesis and/or drug resistance.  In this study, we created genetically 
altered breast epithelial cell line models in order to determine the cellular phenotypes 
that are associated with this variant.  In addition, we queried germline DNA samples 
from breast cancer patients and high-risk families to evaluate the allele frequency of ER 
S118P in the context of breast cancer incidence; we compared this data to publically 
available general population data to assess enrichment of the variant in breast cancer.  
 
Results 
Isogenic targeting and overexpression of ER S118P in human breast epithelial cells 
 In order to study the functional consequences of ER S118P in human breast cells, 
we developed three model cell lines (Figure 4).  First, we created isogenic knock-ins 
within the MCF7 and T47D cell line backgrounds.  The widely used MCF7 and T47D cell 
lines are each derived from a metastatic breast adenocarcinoma and express 
endogenous ER.  We used isogenic gene targeting, via a recombinant adeno-associated 
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viral vector containing the sequence of ESR1 exon 1 modified with the single base-pair 
substitution leading to ER S118P, to produce single-cell clones heterozygous for ER 
S118P (Figure 5).  These cell lines were designated MERSP (MCF7 ER S118P) and TERSP 
(T47D ER S118P) and two individually isolated clones were derived for each.  We also 
derived a “targeted wild-type” clone for each cell line background, which underwent the 
same viral infection and subsequent isolation steps as the variant clones but does not 
carry the variant of interest.  These were designated MWT and TWT, for MCF7 targeted 
wild-type and T47D targeted wild-type, respectively.   
 In addition, we used the non-tumorigenic MCF10A cell line, which was derived 
from fibrocystic breast tissue and does not express ER endogenously, to develop an 
overexpression model of the ER S118P variant.  Our lab has previously established an 
overexpression model of wild-type ER in this cell line, designated ERIN (ER in 
nontumorigenic) (46).  For this study we transfected an isogenic plasmid containing a 
copy of ER S118P cDNA to create two mERIN (mutant ER in nontumorigenic) cell line 
clones (Figure 6).   
 To confirm integration and stable expression of the variant protein in our 
isogenic knock-in models, we performed DNA and cDNA analysis by droplet digital PCR 
and Sanger sequencing as well as protein analysis by Western blot.  All MERSP and 
TERSP clones demonstrate integration of the variant construct within the endogenous 
locus and expression of the variant at the mRNA level via cDNA sequencing (Figure 7).  
One caveat to these models is that genomic DNA analysis suggests that off-target 
incorporation of the viral construct may have occurred in MERSP1, MERSP2, and TERSP2 
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as indicated by higher levels of the variant allele, however it does not appear that any 
additional copies outside of the endogenous locus are expressed since variant cDNA 
levels are similar or slightly lower as compared to wild-type (Figure 8).  In the mERIN 
overexpression model, we confirmed high levels of expression of the variant mRNA and 
protein which are comparable to wild-type ER levels in the ERIN cell lines (Figure 9).   
 
Cells expressing ER S118P grow similarly to wild-type controls 
 To determine whether cells expressing ER S118P have a growth advantage over 
parental cells and whether they respond to estrogen exposure, we compared cell 
proliferation over one to two weeks. MERSP1 and MERSP2 grew similarly to their 
parental and targeted wild-type counterparts, both in the presence of 1 nM 17-beta 
estradiol (E2) and vehicle control (Figure 10).  TERSP2 appears to proliferate more 
rapidly than its parental and targeted wild-type cell lines, while TERSP1 appears to 
proliferate more slowly; while both clones respond to 1 nM E2, the difference in their 
baseline growth rates remains obvious even in the presence of E2 (Figure 11).  This 
discrepancy suggests that other changes within these clonal T47D cell lines are 
responsible for the difference in rate of proliferation, since it is unlikely that this isogenic 
change would produce two opposite responses in the absence of other genetic factors.   
 In our overexpression model, it appears that the mERIN clones grow similarly to 
the wild-type ER containing line ERIN7 in the absence of estrogen, but do not respond to 
100 nM E2 as strongly as ERIN7 (Figure 12).  It seemed that these clones, especially 
mERIN7, actually had a decreased rate of proliferation as compared to baseline growth 
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in the absence of E2, so we explored additional E2 concentrations in order to determine 
whether the optimal E2 dose for these cell lines may be lower than that of ERIN7 (Figure 
13).  Indeed, at 1 nM and 10 nM E2 mERIN7 displays a subtle increase in proliferation 
which is not present at higher or lower E2 concentrations.  mERIN9 responds strongly to 
10 nM E2 and higher concentrations.   
 Overall, it appears that ER S118P does not confer a measurable change in cell 
proliferation at baseline, and the presence of one copy of wild-type ER in our 
heterozygous models is enough to drive a standard estrogen response.  In the absence 
of any wild-type ER, as in our overexpression model, the cells do not respond as strongly 
to estrogen indicating that the variant ER protein may not be as highly activated by its 
traditional ligand.  
 
The ER signaling pathway is intact in ER S118P-expressing cells 
In light of ER’s classical role as a transcription factor and the phosphorylation of S118 as 
a dynamic effector of ER transcriptional regulation, we wanted to assess E2-induced 
expression of a set of genes known to be regulated by ER.  Across a panel of 90 genes in 
the ER signaling pathway, overall expression patterns with vehicle or 10 nM E2 
treatment were consistent between MCF7 and MERSP1 cells (Table 2).  Therefore we 
conclude that there is no significant change in ER-related gene expression pattern 
between the two cell lines, indicating that the networks of transcriptional regulation in 
which ER participates are widely unaffected by the presence of the ER S118P variant as a 
single copy.   
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 The MAP kinase signaling pathway is known to interact heavily with ER signaling 
and is crucial to the overall behavior of a cell.  In order to determine if the ER S118P 
variant affects the activity of this pathway, we probed for levels of phosphorylated Erk 
to represent pathway activation.  After 24 hours of exposure to E2, p-Erk activation is 
relatively consistent across all cell lines and is not associated with expression of ER 
S118P (Figure 14).   
 
Cells expressing ER S118P remain sensitive to hormonal therapies and retain cancerous 
phenotypes similar to wild type ER cells 
With the clinical value of this variant in mind, we sought to determine whether our 
models would respond to hormone therapies commonly used in patients with ER+ 
disease.  Tamoxifen and fulvestrant both interact directly with ER to reduce estrogen 
signaling in breast cancer cells, and other ER mutations have been shown to mediate 
resistance to these therapies (25, 31, 32).  However, none of the ER S118P knock-in cell 
lines displayed any significant differences in response to tamoxifen or fulvestrant at 
various concentrations over nine days of drug treatment (Figure 15).  This response to 
endocrine therapies suggests that ER S118P does not interfere with ER protein-drug 
interaction. 
We were also interested in the migratory abilities of ER S118P cells due to recent 
studies which suggest that ER LBD mutations at Y537 and D538 can increase the 
metastatic potential of cells (47).  In order to determine if the S118P variant could 
similarly contribute to a change in the migratory properties of cells, suggesting a change 
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in metastatic potential, we performed a scratch wound healing assay on the MCF7 cell 
line and its ER S118P derivatives.  In the absence and presence of E2, there was no 
consistent difference in wound closure between cells expressing ER S118P and their 
wild-type counterparts (Figure 16).     
LBD ER mutations also constitutively activate ER leading to E2 independent 
growth in vitro and in vivo (25, 31, 32).   Accordingly, we assessed the ability of the 
S118P variant cells to form tumors in vivo.  Parental MCF7 and MERSP1 cells were 
injected into the mammary fat pad of athymic nude mice, and tumor growth was 
monitored over seven weeks.  As previously described, MCF7 cells were only able to 
form tumors with exogenous estrogen supplementation.  Similarly, MERSP1 cells were 
non-tumorigenic in the absence of estrogen but formed large, rapidly-progressing 
tumors in the presence of estrogen (Figure 17).  The size and growth rate of resulting 
tumors were similar between the parental and variant cell lines.  T47D and MCF-10A cell 
lines could not be assessed due to their inability to grow in athymic nude mice. 
 
The ER S118P allele frequency is comparable between the general population and 
families at high risk for breast cancer 
We and others first noted the ER S118P variant from commercial NGS assays that did 
not employ germline filtering, with the suggestion that this variant was somatic.  Further 
analysis determined that ER S118P was a germline variant in at least one patient, and 
during the course of our study the variant was added to dbSNP under the identifier 
rs200075329, with the clinical significance of this substitution listed as “NA”.  In addition 
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to our functional characterization, we sought to determine the frequency of this variant 
in a population at high risk for breast cancer based upon family history and the absence 
of germline BRCA1 and 2 variants, including pathogenic and variants of unknown 
significance (VUS).  As a missense variant at a highly functional residue in the ER protein, 
we hypothesized that ER S118P may be correlated with either a higher or lower breast 
cancer incidence, due to a change in the signaling pathways that can lead to breast 
cancer development when dysregulated.  
The minor allele frequency of rs200075329, corresponding to the substitution ER 
S118P, varies from 0.0016 to 0.0098 in the general population according to various 
exome sequencing studies (Table 3).  In a cohort of 554 individuals with a family history 
of breast cancer, consisting of 277 breast cancer patients and 277 age-matched 
controls, we identified four heterozygous carriers of the ER S118P variant (Table 4).  In 
our cohort, the minor allele frequency of this variant was 0.004.  Based on these data, 
the variant is not altered in a population of individuals with a high risk of genetic drivers 
of breast cancer.  In addition, of the four carriers of the variant, two were breast cancer 
patients and two were age-matched controls, indicating that presence of the variant is 
not correlated with disease incidence (Table 5).   
 
Discussion 
 The importance of serine 118 phosphorylation in cellular ER dynamics and 
hormone response has been described in numerous studies.  ER is involved in complex 
transcriptional regulation networks and S118 phosphorylation has effects on its 
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coregulatory binding partners, activation time course, and response to ligand binding 
(10).  Phosphorylated ER S118 has also been shown to feed directly back onto levels of 
ER in the cell via changes in degradation dynamics as well as binding to the ESR1 
promoter (48).   
 In prior research, cells expressing a variant of ER with an alanine at residue 118 
(S118A) have displayed significant changes in transcriptional regulation activities, 
estrogen-induced growth stimulation, and response to tamoxifen (8, 41, 49).  Disruption 
of ER phosphorylation at S118 by shRNA has also been shown to confer marked 
phenotypic changes in a breast cancer cell model (50).  To our knowledge, ER S118 
mutants have been studied only in overexpression constructs, meaning they have not 
been under control of the endogenous promotor or had the capacity to interact with 
wild-type ER protein.  We hypothesized that heterozygous knock-in of a naturally-
occurring ER variant, ER S118P, would drive similar changes and so we developed breast 
cancer cell line models containing the variant of interest.  However, the present studies 
have shown that single copy ER S118P is not sufficient to alter proliferation, migration, 
or sensitivity to tamoxifen and fulvestrant of breast cancer cells in vitro.  In addition, we 
do not see significant changes in expression of ER-regulated genes or phosphorylation of 
AKT, all of which are known to be affected by ER S118 phosphorylation dynamics.  Our 
data suggest a slight upregulation of the Erk pathway in response to E2 in heterozygous 
ER S118P cells, but this molecular change does not lead to a detectable cellular 
phenotype in our assays.  Finally, these cells behave similarly to their wild-type 
counterparts as estrogen-dependent xenografts in mice.  
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 We have not found any evidence that this ER variant contributes to a significant 
cellular or molecular phenotype in breast cancer cells according to the heterozygous 
models we have characterized.  Our current hypothesis is that the remaining wild-type 
ER protein in heterozygous models is sufficient to carry out approximately normal 
estrogen signaling in the cell.  This is surprising since ER dimerizes upon activation and 
the majority of ER dimers in a heterozygous cell would contain at least one variant unit.  
However, if the protein structure is not significantly changed by the variant, and 
phosphorylation of only one subunit is sufficient for the regulation of signaling, then it is 
possible that the majority of dimers would function normally without obvious 
phenotypic changes.   
 In addition, we have analyzed a population of individuals diagnosed with and at 
risk for breast cancer based on family history of disease.  We hypothesized that this 
variant may be involved in cellular signaling changes which could be associated with the 
development of breast cancer, and therefore that the variant may have an altered 
prevalence in a population representing familial breast cancer and its genetic drivers.  
However, the variant was present at a minor allele frequency of 0.004, consistent with 
the average range of minor allele frequencies identified in the general population.  This 
result suggests that ER S118P is unlikely to be a modifier of breast cancer development.   
 In light of these results, this variant may be benign in breast cancer patients.  It 
does not appear to function as a driver or supressor of any particular characteristics of 
the cancer which we have studied.  Therefore, we recommend that patients who are 
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found to carry this variant should be treated according to standard of care, since this 














































                
 
                                          
 
Figure 4: ER S118P cell line panel schematic. From each parental cell line used in this 
study, three additional cell line derivatives were obtained. MERSP1, MERSP2, TERSP1, 
and TERSP2 express heterozygous ER S118P while MWT and TWT are homozygous WT 
at that locus but underwent the same viral targeting and screening process. mERIN7 and 
mERIN9 exogenously express ER S118P while ERIN7 exogenously expresses WT ER via 















Figure 5: Recombinant AAV targeting strategy for knock-ins.  In our knock-in strategy, 
one endogenous allele of ESR1 undergoes homologous recombination with a 
recombinant targeting vector consisting of the adeno-associated viral backbone 
modified to contain a homologous region of ESR1 and a neomycin resistance cassette. 
After selecting targeted cells with neomycin and screening for successful knock-in, the 
remaining cells are treated with Cre recombinase and left with a small LoxP scar 

















Figure 6: ER S118P overexpression vector. In our overexpression strategy, a plasmid 
containing the modified ER S118P cDNA was stably transfected into MCF10A cells.  This 
vector contains an internal ribosomal entry site (IRES) followed by a neomycin 








Figure 7: Validation of MERSP and TERSP clones. All cell lines were confirmed by PCR 
and Sanger sequencing.  A) The targeted allele can be detected by PCR due to the LoxP 
scar within the intron immediately following ESR1 exon 1, which results in a size 
difference in PCR product. B) Each cell line was additionally validated by Sanger 
















Figure 8: Allelic ratios of ER S118P cell line panel. Droplet digital PCR analysis of the 
MERSP and TERSP cell lines indicates that MERSP1, MERSP2, and TERSP2 have additional 
off-target integration of the ER S118P homology construct elsewhere in the genome.  
Each event represents a droplet containing an amplicon with genotype S118P (blue) or 
WT (green).  A) Genomic DNA analysis shows that MERSP1, MERSP2, and TERSP2 have a 
ratio of approximately 2:1 between ER S118P and WT ER. A 1:1 ratio would be expected 
for a true heterozygous cell, as seen in TERSP1. B) Complementary DNA analysis shows 
that the additional integrant suggested in three cell lines in (A) is not expressed, as the 









Figure 9: Validation of mERIN clones. (A) Complementary DNA analysis by droplet digital 
PCR shows that ERIN9 and ERIN7 (now shown) express only WT ER, while mERIN9 and 
mERIN7 (not shown) express only ER S118P.  (B) Sanger sequencing of cDNA from mERIN7 
and mERIN9 (not shown) confirm that the transcript carries the sequence resulting in ER 
S118P protein.  (C) Western blot analysis confirms that ERIN7, mERIN7, and mERIN9 express 









Figure 10: MCF7 and derivatives have similar growth rates in the absence and presence of 
1 nM estrogen. MCF7-derived cell lines were seeded in 12 well plates in media 
supplemented with 5% serum and vehicle (A) or 1 nM E2 (B).  Increase in proliferation in 
response to E2, as shown in (C) by normalizing cell counts in the presence of E2 to cell counts 
from baseline proliferation, remains similar between cell lines. Data are shown as mean + SD 









Figure 11: T47D and derivatives have variable growth rates. T47D-derived cell lines were 
seeded in 12 well plates in media supplemented with 5% serum and vehicle (A) or 1 nM E2 
(B).  In the absence and presence of 1 nM E2, TERSP1 proliferates at a slower rate than T47D 
and T47D WT, while TERSP2 proliferates at a faster rate. However, response to E2, as shown 
in (C) by normalizing cell counts in the presence of E2 to cell counts from baseline, is similar 
between cell lines. Data are shown as mean + SD of three replicates, and curves are 









Figure 12: mERIN clones do not respond to 100 nM E2. (A) Baseline proliferation in the 
absence of E2 is similar between ERIN7, mERIN7, and mERIN9.  (B) ERIN7 responds strongly 
in the presence of 100 nM E2 while mERIN7 displays a lower responses, and there is no 
effect on mERIN7 or the non-ER expressing MCF10A control.  (C) Response to E2, shown as 
relative proliferation with 100nM E2 normalized to baseline proliferation, is only present in 
the ERIN7 cell line. Data are shown as mean + SD of three replicates, and curves are 













Figure 13: Additional concentrations of E2 for ERIN and mERIN clones. Additional lower 
concentrations of E2 reveal an increased response from the mERIN clones at 10 nM E2, 




























Table 2: Transcriptional activation by E2 in MCF7 and MERSP1. E2-induced transcriptional 
activation in cells treated with 10 nM E2 for 90 minutes (as measured by comparing to cells 

















Figure 14: ER S118P cell lines maintain ER and Erk signaling patterns. After 24 hours of E2 
treatment, all cell lines had reduced total ER levels and slightly increased phospho-Erk levels. 
Subtle variations do not correlate with ER S118P genotype. Blots are representative of three 






Figure 15: ER S118P cells maintain sensitivity to tamoxifen and fulvestrant.  A) MCF7 cells 
and B) T47D cells and all targeted cell line derivatives were treated with 1 nM E2 and 
variable concentrations of tamoxifen and fulvestrant over nine days. Data are shown as 
mean + SD of three replicates relative to cells treated with 1 nM E2 + drug vehicle, and 















Figure 16: ER S118P does not affect cell migration toward a wound. MCF7 and targeted cell 
line derivatives were seeded in 6 well plates with and without 1 nM E2.  Once confluent, 
wells were scratched with a pipet tip and monitored over 16 hours for wound closure.  A) 
Percent healing of the wound by area was determined by subtracting cell coverage at 0 
hours from cell coverage at 16 hours.  B) Representative images of scratch wound healing.  


















Figure 17: MCF7 and MERSP1 xenograft formation is estrogen-dependent. MCF7 and 
MERSP1 cells were injected into nude mice with and without estrogen supplementation 
implants and mice were monitored for 45 days.  Both cell lines formed tumors only in the 
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Table 3: ER S118P variant allele frequency in the general population. Publicly available 




























































Materials and Methods 
 
Cell culture 
MCF7, T47D, and MCF10A parental cell lines were obtained from ATCC and verified via 
short tandem repeat profiling by the Johns Hopkins Genetic Resource Core Facility. All 
cells were grown in 5% CO2 at 37 C.  MCF7 and T47D lines and their derivatives were 
maintained in DMEM containing 5% fetal bovine serum and 1% penicillin/streptomycin.  
The MCF10A line and its derivatives were maintained in DMEM:F12 containing 5% horse 
serum, 1% pen/strep, epidermal growth factor at 20 ng/ml, insulin at 10 μg/ml, 
hydrocortisone at 0.5 μg/ml, and cholera toxin at 0.1 μg/ml. Cells were arrested in clear 
DMEM:F12 with 1% charcoal dextran treated fetal bovine serum and 1% pen/strep and 
assayed in clear DMEM:F12 with 10% charcoal dextran treated fetal bovine serum and 
50 
 
1% pen/strep (all MCF10A media contained insulin, cholera toxin, and hydrocortisone at 
the concentrations stated above, but EGF was omitted in arrest and assay formulations).   
 
Gene targeting 
MCF7 and T47D parental cell lines were genetically altered using a recombinant AAV 
vector containing the T>C single base-pair substitution in ESR1 exon 1 resulting in ER 
S118P.  Cells were targeted, screened, and validated as previously described (55).  Two 
independently derived clones containing the variant and one targeted wild-type clone 
were isolated from each parental cell line and confirmed via gDNA and cDNA analysis by 
Sanger sequencing and droplet digital PCR.  Targeted cells were maintained in DMEM 
media as described above.  
 
Overexpression  
MCF10A cells were transfected using Fugene 6 (Promega) with the pIRESneo3 vector 
containing a copy of ER cDNA modified with the S118P variant.  Cells with stable 
expression of the neomycin resistance gene were selected with Geneticin (Life 
Technologies) at 120 ug/ml and two independently derived clones were validated for 
stable expression of ER S118P via cDNA ddPCR and presence of total ER but absence of 
phosphorylated ER S118 via immunoblotting.  ERIN cell lines established previously in 
our lab overexpress wild-type ER from the same parent vector and were used as the 
wild-type control for these cells (46). ERIN and mERIN lines were maintained in 
DMEM:F12 media as stated above with the addition of Geneticin at 120 µg/ml. 
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Cell proliferation and drug response assays 
17-beta estradiol, 4-hydroxytamoxifen, and fulvestrant were obtained from Sigma-
Aldrich and diluted according to manufacturer recommendations.  Cells were seeded at 
low confluency (3,000 MCF7 cells/well, 50,000 MCF10A cells/well, 60,000 T47D 
cells/well) in 12 well cell culture plates in arrest media for 24 hours.  Cells were 
visualized on day 0 and estrogen/drug/vehicle conditions were added at the stated 
concentrations in assay media. Media containing estrogen/drug was replaced every 
three days.  After the stated number of days, cells were trypsinized, uniformly 
resuspended, and counted using the Vi-Cell XR (Beckman Coulter).  All results are an 
average of cell counts from triplicate wells.    
 
Scratch assays 
Cells were seeded at 50% confluency in 6 well cell culture plates in assay media for 24 
hours.  Cells were then visualized to confirm 90% confluency and placed in assay media 
containing 1 nM 17-beta estradiol (E2) or vehicle.  After 8 hours, a 200 uL pipet tip was 
dragged across the plate surface, creating two perpendicular scratches in the lawn of 
cells; cells were then rinsed twice with clear HBSS to remove floating cell debris and 
media containing E2 or vehicle was replaced.  Two visual fields per well were imaged at 
time 0 and again after 16 hours.  Images were then analyzed in ImageJ using the MiToBo 
plugin for percent of field containing cells, and timepoints were compared in order to 





Cells were seeded in arrest media for 24 hours, then treated as stated.  Cells were then 
collected and protein lysates prepared in Laemmli buffer.  Lysates were analyzed by 
Western blot as described previously (56).  Primary antibodies used in this study are: 
phospho-ERα S118 (Cell Signaling 2511), ERα (Cell Signaling 8644), phospho-Erk (Cell 
Signaling 4370), Erk (Cell Signaling 9102), GAPDH (Cell Signaling 5174).  
 
Quantitative PCR  
Cells were seeded in arrest media for 24 hours, then media was replaced with 10% CD 
assay media for 24 hours, then cells were exposed to 17-beta estradiol at 1 nM for 45 
minutes.  Cells were then trypsinized and resuspended, and RNA and cDNA were 
prepared.  cDNA was then added to a PrimePCR pathway plate for estrogen receptor 
signaling (Bio-Rad) along with SsoAdvanced Universal Sybr Green Supermix (Bio-Rad) 
and amplified and analyzed according to the Bio-Rad protocol.   
 
Xenografts 
MCF7 cells were suspended in Geltrex LDEV-Free Reduced Growth Factor Basement 
Membrane Matrix (Life Technologies) and one million cells in a volume of 200 ul were 
injected subcutaneously into the mammary fat pad of 8- to 10-week-old female athymic 
nude mice (Harlan Laboratories) with and without slow-release estrogen implants as 
previously described (56). Tumor volumes were calculated as a pseudosphere from 
length, width, and height measurements.  All animal experiments were performed in 
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accordance with institutional guidelines and The National Institutes of Health Guide for 
the Care and Use of Laboratory Animals guidelines. 
 
Statistics 
Statistical analyses were performed using GraphPad Prism 6 software.  Relative 
proliferation rates were analyzed by two-way ANOVA.  Error bars represent ± SD.  None 
of the data analyzed reached a significance level of P ≤ 0.05.    
 
Cohort genotyping 
Genomic DNA extracted from lymphocytes was obtained from Kala Visvanathan at the 
Johns Hopkins Center for Clinical Cancer Genetics and Prevention.  Samples were 
analyzed via droplet digital PCR on the QX200 platform (Bio-Rad) per the manufacturer’s 
protocols for probe-based ddPCR.  Primers and probes used were as follows: forward 
primer (5’-CACTCAACAGCGTGTCT-3’), reverse primer (5’-CTCGTTCTCCAGGTAGTAG-3’), 
wild-type probe (5’-AGCTGTCGCCTTTCCTGCAG-3’), variant probe (5’-
AGCTGCCGCCTTTCCTGCAG-3’).   
 
Population data 
The authors would like to thank the Exome Aggregation Consortium and the groups that 
provided exome variant data for comparison. A full list of contributing groups can be 
found at http://exac.broadinstitute.org/about. 
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